BPH - Benign Prostatic Enlargement - Results from #2760

REVIEW UroToday

Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-Year results from the randomized, double-blind Combination of Avodart and Tamsulo April 25, 2011

The impact of prostate size, median lobe, and prior benign prostatic hyperplasia intervention on robot-assisted laparoscopic prostatectomy: Technique and outcomes - Abstract April 21, 2011

Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action - Abstract April 20, 2011

Photoselective vaporization for prostatic obstruction with the 120-W lithium triborate laser: 1-Year clinical outcomes - Abstract April 19, 2011

CURy 2011 - Is GreenLight XPS now better for the patients or the surgeons? - Slide Presentation April 12, 2011

BJUI Mini Reviews - Risk stratification for benign prostatic hyperplasia (BPH) treatment April 5, 2011

CURy 2011 - The speed of light just went faster - Slide Presentation March 29, 2011

CURy 2011 - GreenLight laser prostate surgery – the transition from PV to XPS - Slide Presentation March 29, 2011

CURy 2011 - GreenLight laser for the treatment of BPH: Functional results with long term follow up - Slide Presentation March 29, 2011

CURy 2011 - Do we need more and more laser to treat BPH? - Slide Presentation March 25, 2011

Arteriosclerosis related factors had no clinical significant correlation with resistive index in symptomatic benign prostatic hyperplasia - Abstract March 15, 2011

Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia - Abstract March 14, 2011

Major depression drives severity of American Urological Association Symptom Index - Abstract March 11, 2011

Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: Results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe - Abstract March 10, 2011

New advances in benign prostatic hyperplasia: Laser therapy - Abstract March 9, 2011

Reduced levels of 5-α reductase 2 in adult prostate tissue and implications for BPH therapy - Abstract March 8, 2011

Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A 1-year, open-label extension study - Abstract March 7, 2011

Human papillomavirus in benign prostatic hyperplasia and prostatic adenocarcinoma patients - Abstract February 22, 2011

Progression of null or mild lower urinary tract symptoms indicative of benign prostatic hyperplasia after 2 years of follow-up in non-treated men aged 40 years or older - Abstract February 17, 2011

A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder March 8, 2010

Page 139 of 140